Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01842711 · ClinicalTrials.gov registry record
Cumulative Irritation Patch Test
A clinical trial, sponsored by Chattem.
- Completed
- Registry status
- 224
- Enrollment target
NCT01842711: Completed study, sponsored by Chattem.
NCT01842711 is a clinical trial that has completed, run by Chattem. The registered enrollment target is 224 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01842711 has completed, sponsored by Chattem.
- COMPLETED
- Registry status
- 224 participants
- Enrollment target
Study Summary
A Cumulative Patch Test with a Challenge Phase is a test devised to ascertain if a chemical agent or agents have the potential to cause contact irritation or contact allergy in the skin. Allergy is only elicited in immunologically competent individuals who have become sensitized through exposure to the chemical agent at a sufficient concentration and for a sufficient duration of time.
Primary Outcome
This will be measured by the evaluation of the test sites (skin)by a trained assessor with a predetermined scale for skin irritation.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 224 participants |
| Start Date | 2012-09 |
| Est. Completion | 2012-11 |
What the finished NCT01842711 record still lists
NCT01842711 is an observational study that tracks outcomes without assigning an intervention. The registered 224 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01842711 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01842711 about?
NCT01842711 is a clinical study titled "Cumulative Irritation Patch Test". A Cumulative Patch Test with a Challenge Phase is a test devised to ascertain if a chemical agent or agents have the potential to cause contact irritation or contact allergy in the skin. Allergy is only elicited in immunologically competent individuals who have become sensitized through exposure to ...
What is the current status of trial NCT01842711?
This trial is currently completed. The enrollment target is 224 participants. The study started on 2012-09. Estimated completion is 2012-11.
Who is sponsoring clinical trial NCT01842711?
This trial is sponsored by Chattem, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02706561 · 224 participants · NA
Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery
- NCT04140344 · 224 participants · NA
The NOTICE Study: Neurosurgery and OrThopedIcs Communication Evaluation Study Following Lumbar Fusions
- NCT04915183 · 224 participants · Phase 2
Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
- NCT05519878 · 224 participants · NA
Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia